Cipla's Advair Generic US Debut May Be Pushed Out But 'Value Intact'
Executive Summary
Cipla to pursue two-site, de-risked filing approach for large respiratory assets even as it awaits an FDA compliance classification for its Indore facility, which will determine the launch timelines for its much-awaited generic Advair in the US.
You may also be interested in...
Cipla Readies gSymbicort, Semaglutide Amid Sale Speculation ‘Distraction’
Cipla’s US business scales new peak in Q2 amid strong showing overall even as the promoter group stake sale speculation is becoming a 'distraction'. The company has new peptide assets, among others, in the wings while management also points to traction in the 'mRNA journey'.
Cipla Readies gSymbicort, Semaglutide Amid Sale Speculation ‘Distraction’
Cipla’s US business scales new peak in Q2 amid strong showing overall even as the promoter group stake sale speculation is becoming a 'distraction'. The company has new peptide assets, among others, in the wings while management also points to traction in the 'mRNA journey'.
'Evergreen' Cipla: Chair Hamied Talks New Technologies Amid 'Speculative' Sale News
Cipla’s chief Dr Yusuf Hamied talks about investments in new technologies that will shape the company’s future, terming reports of a stake sale as “speculative" but not going as far as an outright denial.